Inspira Technologies Oxy BHN Ltd (IINN) 股票分析

公司概述

Inspira Technologies Oxy B.H.N. Ltd. operates as a specialty medical device company focused on the research, development, manufacturing, and marketing of proprietary life support technologies specifically designed for the treatment of acute respiratory failure within the Israel market. The company functions within the broader Healthcare sector, more specifically in the Medical Devices industry, positioning itself to address critical needs in respiratory care infrastructure. As of the latest available data, the entity possesses a market capitalization of $17.74M, generates annual revenue of $289,000, and employs a workforce of 34 individuals. These financial metrics indicate that the company is a micro-cap entity with a very small revenue base relative to its market valuation, suggesting a high degree of market risk and significant volatility inherent in its current operational scale.

财务健康

The company reports a trailing twelve-month revenue of $289,000, yet it simultaneously records a net income of $-13,220,000 and an EBITDA of $-13,473,000, revealing a severe structural disconnect where operating expenses vastly exceed gross earnings. This massive disparity between revenue and net income highlights an extreme cost structure where fixed costs, likely related to R&D or manufacturing overhead, consume the entire revenue stream while generating substantial losses. The firm's free cash flow stands at $-5,668,375, indicating a consistent burn rate that limits financial flexibility and necessitates external capital raises to sustain operations. Despite these losses, the company maintains a cash reserve of $3.16M against total debt of $480,000, though the debt-to-equity ratio of 20.66 suggests a highly leveraged capital structure relative to its equity base. Profitability metrics are critically negative, with a gross margin of 0.7%, an operating margin of -4713.8%, and a profit margin of 0.0%, signaling that the company is currently unable to cover its direct costs or generate any return on sales. Liquidity is supported by a current ratio of 1.56, which indicates the company can cover its short-term liabilities with assets, yet this liquidity does not offset the underlying profitability issues. Return on Equity is reported at -397.9% and Return on Assets at -127.0%, metrics that demonstrate management is currently unable to generate value for shareholders or utilize assets effectively to produce earnings.

估值评估

Valuation metrics for Inspira Technologies Oxy B.H.N. Ltd. present a complex picture due to the absence of earnings, with the trailing P/E ratio listed as N/A and a forward P/E of -0.58. The negative forward P/E and the gap between the unavailable trailing P/E imply that earnings are currently negative and the market is pricing the stock based on alternative factors rather than profitability expectations. Investors should note the price-to-book ratio of 6.26, which indicates that the market is valuing the company at a significant premium over its tangible book value despite its loss-making status. Alternative valuation metrics further highlight this discrepancy, with a price-to-sales ratio of 61.37 and an EV/EBITDA of -1.12, suggesting the stock is priced heavily relative to its minimal revenue generation and negative cash flows. Price volatility is evident in the 52-week trading range, which spans from a low of $0.34 to a high of $1.65, meaning the current price sits within a range that reflects substantial historical fluctuation. The stock exhibits a beta of 2.33, indicating that its price movements are more than twice as volatile as the broader market, a characteristic often observed in small-cap medical device companies with negative earnings.

Growth & Income

Growth rates for both revenue and earnings are listed as N/A, as the company does not have sufficient historical data to calculate year-over-year growth percentages. The absence of positive earnings growth relative to revenue is expected given the company's current state of significant losses and negative net income. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning no cash is distributed to shareholders, and the firm retains all earnings—or in this case, absorbs all losses—into the business. Consequently, the company reinvests its limited financial resources, primarily from its cash reserves, back into its research and development activities for life support technologies rather than providing income to investors. The overall growth and income profile is characterized by a lack of income generation and undefined growth metrics due to the company's early-stage financial performance and negative operational history.